The possible synergistic action of sex hormones and glucagon-like peptide-1 (GLP-1) agonists on body mass decline in patients with type 2 diabetes mellitus.
Level 5 - mechanism / opinion, no new human data
Mechanism-based reasoning and theoretical hypothesis with no original human or animal data
PubMed 31443779 · doi:10.1016/j.mehy.2019.109308
What was done
The authors formulated a theoretical hypothesis regarding the potential synergistic effect of combining glucagon-like peptide-1 (GLP-1) agonists and sex hormone replacement therapy on weight loss in patients with type 2 diabetes mellitus.
What was found
No original empirical or experimental data were collected; no numerical results are reported in the abstract.
Why it matters
It outlines a mechanistic rationale for exploring combination therapy of GLP-1 agonists and sex hormones to address obesity in type 2 diabetes.
Limits
This is a speculative hypothesis paper published in Medical Hypotheses containing no primary clinical trials, observational cohorts, or laboratory measurements.
Cited by
- context Studies show that women taking GLP-1 receptor agonists like tirzepatide achieve greater weight loss when also receiving hormone replacement therapy (HRT).